Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Investor Day (January 2025)
38 slides from Angiodynamics's investor day presentation, Jan 8, 2025
Slide 1: Revolutionizing Prostate Care: Transforming Treatment. Driving Value
IWANOKNIFE Irreversible Electroporation (IRE) PROSTATE Investor Event Revolutionizing Prostate Care: Transforming Treatment. Driving Valu
Slide 2: Notice Regarding Forward-Looking Statements
2 2 Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business st
Slide 3: Pursue Larger, Faster Growing Markets
3 Edit Title 3 Pursue Larger, Faster Growing Markets Significantly expanded the scope of our Med Tech portfolio through R&D, M&A, and clinical/regulatory initiatives by entering the mechanical thrombectomy market, capitalizing on the solid PAD market, and building on the under-penetrated prostate fo
Slide 4: Med Tech TAM: PAD, VTE and Prostate Care
4 4 Peripheral Artery Disease (PAD) $760M US TAM Venous Thromboembolism (VTE) $5.3B US TAM Prostate Care $2.7B Global TAM ($780M US) A leading medical technology company driving sustained growth and profitability through its commitment to expanding treatment options, enhancing patient outcomes, and
Slide 5: An innovative, versatile, hour-long prostate treatment
5 To Become An innovative, versatile, hour-long prostate treatment *1,2 *Treatment time does not include patient prep, anesthesia initiation or recovery room time. 1-2 See reference page
Slide 6: The First Non-Thermal, Radiation Free Ablation Technology
6 The First Non-Thermal, Radiation Free Ablation Technology The only FDA cleared technology that uses electricity to destroy prostate tissue Robust IP Portfolio Clinical Outcomes Patients and Physicians Need Over 2,600 patients have been treated under protocol with 32 peer-reviewed studies The only
Slide 7: NanoKnife System indications for use vary per region
7 *The NanoKnife System indications for use vary per region. Please refer to the indications for use for approved use per region
Slide 8: The most diagnosed male cancer
The most diagnosed male cancer in 112 countries, including the U.S.4 annual diagnoses in the U.S. annual diagnoses 5 worldwide Incidence projected to double by 20404 The projected rise in prostate cancer cases cannot be prevented by lifestyle changes or public health interventions. -The Lancet Commi
Slide 9: Radical surgery or external beam radiation therapy
Radical surgery or external beam radiation therapy 8 REV 01 GL/ON/PR/3126 7 8 9 † † 7-9 See reference page † AngioDynamics Internal Estimates
Slide 10: Active Surveillance vs Definitive Treatment
Active Surveillance Possibility of cancer progression Definitive Treatment Risk of serious long term urological side effects 5 years 50.2% 10 years 38.7% 15 years 33.7% Erectile Dysfunction Urinary Incontinence Baseline 34% 1-year 85% Erectile Dysfunction Urinary Incontinence Baseline 30% 1-year 71%
Slide 11: Focal therapy targeting the index lesion
Which aims to destroy the index lesion while preserving the natural anatomy, continence and erectile function14 Advanced Imaging Patient Selection “Index Lesion” Most lethal metastatic prostate cancers originate from a single cell within the ‘Index Lesion’ of the prostate.15 Active Surveillance Defi
Slide 12: Focal therapy potential clinically appropriate patients
‘17 ‘18 ‘19 ‘20 ‘21 ‘22 ‘23 ‘24 ‘25 of diagnosed patients undergo a focal therapy each year † 10 REV 01 GL/ON/PR/3126 † AngioDynamics Internal Estimates † Focal Therapy† (7,000) Potential Clinically Appropriate Patients
Slide 13: Limits of today's focal therapy options
Learning Curve Time Constraints Reproducible Results Today, focal therapy options are only ideal for a specific segment of the prostate. A piecemeal approach to focal therapy is prohibitive to broader physician adoption and limits patien ts’ access to care. Increased Costs Complex Integration Suppor
Slide 14: Enable Broad Physician Adoption And Improved Care
That Can Enable Broad Physician Adoption And Improved Care For Patients 1 2 3 1,2 10 REV 01 GL/ON/PR/3126 1-3, 16-18 See reference page 1,16 1,3,17,18,19
Slide 15: One-Of-A-Kind Technology
reversible Electroporation (IRE) PROSTATE One-Of-A-Kind Technology
Slide 16: The NanoKnife System Resources
The NanoKnife System Resources Nanoknife System Prostate NanoKnife System Mechanism Procedure Animation of Action Animation NANOKNIFE reversible Fectroporatic
Slide 17: IRE selectively targets cell membranes
Sufficient voltage permanently opens the ion channels of the cell IRE selectively targets cell membranes20 16 REV 01 GL/ON/PR/3126 20 Cell loses homeostasis leading to cell death20 20 – See reference page
Slide 18: Aims to Preserve the Nerves, Urethra, and Urinary Sphincters
And Aims to Preserve the Nerves, Urethra, and Urinary Sphincters 21,22 21,22 - See reference page 16 REV 01 GL/ON/PR/3126
Slide 19: Backed by Real World Experience and Compelling Clinical Evidence
reversible Electroporation (IRE) PROSTATE Backed by Real World Experience and Compelling Clinical Evidence
Slide 20: Regulatory Clarity in Prostate Tissue Ablation
In Prostate Tissue Ablation *For detailed information, refer to the FDA's guidance document titled "Clinical Investigations for Prostate Tissue Ablation Devices." Regulatory Clarity Encourages Innovation Prioritizes Patient Safety The NanoKnife System with six outputs is indicated for surgical ablat
Slide 21: PRESERVE pivotal study of NanoKnife for prostate ablation
Pivotal study of the NanoKnife System for ablation of prostate tissue in patients with intermediate-risk prostate cancer 20 REV 01 GL/ON/PR/3126
Slide 22: The PRESERVE Study Experience
The PRESERVE Study Experience IRE IRE IRE IRE Avg. Procedure Time 54.1 Minutes Avg. # of Electrodes 4.3 Avg. Procedure Time 54.1 Minutes Avg. # of Electrodes 4.3 Avg. Procedure Time 54.1 Minutes Avg. # of Electrodes 4.3 Mean Procedure Time Mean # of Electrodes 54.1 Minutes 4.3 *Treatment time does n
Slide 23: Treatment Utilizes Existing Imaging and Biopsy Skills
The Treatment Utilizes Existing Imaging and Biopsy Skills NanoKnife Electrodes P rostate Bladder Transrectal Ultrasound Probe Grid Subjects Clinical Sites IRE-naïve Sites 121 17 14 The PRESERVE Study Experience 20 REV 01 GL/ON/PR/3126 Gleason 3+4 80.2% Gleason 4+3 19.8% Stepper 1,16 1,16 – See refer
Slide 24: IRE has the lowest impact on sexual function
IRE has the lowest impact on sexual function compared to Hifu and Cryo And provides strong ablation of targeted tissue A 2024 meta-analysis and systematic review of all primary studies reporting outcomes for focal therapy 23 * *All IRE Data Collected Utilizing The NanoKnife System 20 REV 01 GL/ON/PR
Slide 25: U.S. Experience Confirms Strong International Data
U.S. Experience Confirms Strong International Data 1,16,17,18,19 *Data on file – Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue (PRESERVE) 20 REV 01 GL/ON/PR/3126
Slide 26: Enable Broad Physician Adoption And Improved Care For Patients
That Can Enable Broad Physician Adoption And Improved Care For Patients 1 2 3 High level of experience with needle-based procedures Uses existing imaging and biopsy skills Reliable ablations with no skip lesions or heat sink Increased margin expansion without negatively impacting erectile or urinary
Slide 27: Commercial Opportunity
reversible Electroporation (IRE) PROSTATE Commercial Opportunity
Slide 28: Capital Equipment and Single-Use Disposable Electrodes
Capital Equipment Single-Use Disposable Electrodes (2-6 per procedure) Hardware Software Accessories Recurring Revenue 28 REV 01 GL/ON/PR/3126
Slide 29: Key Market Penetration Tactics
1 Regulatory Approvals Key Market Penetration Tactics *Based on potential procedures in countries with active NanoKnife users. Market Access Strong Go-To Market Strategy 28 REV 01 GL/ON/PR/3126
Slide 30: NanoKnife System indication for prostate tissue ablation
The NanoKnife System is indicated for the ablation of prostate tissue in patients with intermediate risk prostate cancer. The NanoKnife System with six outputs is indicated for surgical ablation of soft tissue, including prostate tissue. 32 publications across 2,642 patients Pivotal Study of the Nan
Slide 31: US Coverage, Coding and Payment
US Coverage: US Coding: US Payment: IRE included in the Medicare Fee Schedules for ASC and Hosp Outpatient settings effective 01/2021 IRE CPT 1 codes for prostate and for liver approved 9/2024 and effective 01/2026 APC 5362 – HOPPS 2025 national average payment $10,411 (+6% yoy) Canada: WIRED Trial:
Slide 32: Direct Sales, Patient Awareness, Physician Education
Direct Sales & Partnerships Patient Awareness Physician Education There is an increasing trend toward using the internet as the first source of health information compared to family/friends/coworkers, health care professionals, and traditional media. -US Health Information National Trends Survey Enh
Slide 33: Active Sites at the End of Q2 2024
33 ‡ Internal AngioDynamics Data As of Q2 2024 ASC 20% Private/Public 24% Academic Center 56% Active Sites at the End of Q2 2024 Create a Strong Opportunity for Growth in the Future Physician Acquisition Procedural Adoption Active Facilities‡ Active Physicians ‡ Care Site‡ REV 01 GL/ON/PR/3126
Slide 34: Investment Highlights
34 Large and growing addressable market Innovative, versatile, ~hour-long prostate treatment* Addresses an unmet need for physicians, their facility, and their patients Backed by strong clinical evidence Upcoming Category 1 Payment effective 01/2026 Strong revenue model built for growth Commercial t
Slide 35: References
Data on file - Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue (PRESERVE) Scheltema, Matthijs J et al. “Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments.” Diagnostic and interventional radiology
Slide 36: References
Cussenot O and Stricker P. Irreversible Electroporation for Patients with Localised Prostate Cancer: Expert Opinion on this Versatile Therapeutic Approach. EMJ Urol. 2021;9(1):56- 62. Fainberg, Jonathan et al. “Targeted Ablation Using Ultrasound-Guided Irreversible Electroporation of Index Tumors (T
Slide 37: Important Safety Statements and Indications for Use
Statements: The NanoKnife System must be operated by properly qualified personnel only. Caution: Federal (USA) law restricts the use of the system by or on the order of a physician. Refer to Directions for Use and/or User Manual provided with the product for complete Instructions, Warnings, Precauti
Slide 38: Use of Generator Safety Information
Use of Generator (including Electrocution Hazard) No modification of this equipment is allowed. To avoid risk of electric shock, this equipment must only be connected to a supply mains with protective earth. The Generator internally produces voltages that are dangerous and may be fatal. The Generato